Search
Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond
New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how he thinks Nucleome is in a unique...
Sep 17, 2024
Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating
CEO Iain Kilty describes the keys to intervening in cell metabolism, and discusses pipeline assets such as a PKM2 for atopic dermatitis...
Sep 17, 2024
Since 1986, Madrid's PharmaMar has been searching the world's oceans for new cancer medicines - it has already led to three approved drugs
Managing Director Luis Mora walks us through the company's development process, from divers in the ocean, to sample testing, and...
Sep 17, 2024
Getting a general overview of protein splicing at Barcelona's SpliceBio
Co-Founder & CEO Miquel Vila-Perelló describes the rationale for protein splicing , how it works, and he shares an overview of the...
Sep 16, 2024
From Biocom California's Women's Health Conference: The Co-Founder and CEO of AccendoWave describes the importance of understanding women's pain data
Martha Lawrence's company has databases on women in pain and maternal health in pain. She explains how customers such as the government...
Sep 16, 2024
Veracyte's CEO talks about ESMO data from its prostate cancer diagnostic that could change how metastatic prostate cancer is treated
Marc Stapley explains how the company's Decipher Prostate Test, already successful commercially in localized prostate cancer, could help...
Sep 16, 2024
In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor
CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly...
Sep 14, 2024
Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress
He discusses data from the Nectin-4 targeting zelenectide pevedotin program, Nectin-4 + CD137, and EphA2.
Sep 14, 2024
The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens
John Lewis describes the limitations of AAV and LNPs, and how the Entos construct is meant overcome them. Plus, a summary of the...
Sep 13, 2024
Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development
Danny Bar-Zohar describes Merck KGaA's three pillars of healthcare research: oncology, neurology, and immunology. Plus, the advantages of...
Sep 12, 2024
London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study
CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target....
Sep 12, 2024
The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer
Bob Duggan and Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the...
Sep 10, 2024
Berlin based T-knife Therapeutics is carrying on the tradition of German leadership in TCR based technologies in oncology
CEO Thomas Soloway and CTO Elisa Kieback walk us through what makes T-knife unique in the construction and manufacturing of its cell...
Sep 10, 2024
Andreas Eckert, founder of Eckert & Ziegler, is an expert in radio isotopes and how they are used in medicine. A subsidiary, Pentixapharm, is about to be spun off into is own public company
From Berlin, he describes the various isotopes that are used in medicines and discusses the technological advances that have lead to a...
Sep 9, 2024
Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label
CEO Eric Dube describes the drug's mechanism, the new population, and what else Travere is working on that will have near-term catalysts.
Sep 6, 2024
The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity
Pierre d'Epenoux describes how activating butyrophilin modulates γδ t-cells, science that has largely been explored in Marseille, and...
Sep 6, 2024
Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology
Hervé Brailly covers lacutamab, monalizumab, the company's NK engager programs, and more.
Sep 6, 2024
Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest
CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector...
Sep 5, 2024
With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases
CEO Stéphane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the...
Sep 5, 2024
Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system
CEO Pierre Belichard describes the scientific underpinnings of this idea, and how it has lead to Enterome's programs, including one in...
Sep 5, 2024
.png){kind=logo}
